Long COVID is emerging as a significant challenge in public health. Estimates suggest that it may impact as many as 18 million Americans. Senator Todd Young has taken notice, pressing Secretary Kennedy to make Long COVID research a priority during his confirmation hearing. Recently, at a budget hearing, Young received updates from the Secretary about efforts to identify potential biomarkers associated with the condition. This commitment is promising.
For many, the COVID-19 pandemic feels like a past event, yet for countless Americans, the effects are ongoing and severe. Long COVID manifests in numerous distressing symptoms, including cognitive dysfunction, extreme fatigue, and various vascular issues. Shockingly, there is no known diagnostic test, and the pathogenesis of the disease remains poorly defined, leading to no established therapies to combat it.
The situation is reminiscent of the early days of the AIDS epidemic. Much like those initial struggles, the current Long COVID crisis has led many doctors, including those with service backgrounds, to redirect their medical focus toward helping patients experiencing these debilitating long-term symptoms.
Three decades ago, the response to AIDS involved a concerted effort from academia, government agencies, and industry, ultimately shifting HIV/AIDS from a terminal illness to a manageable condition. This transformation was possible because of dedicated research and innovation funded by the government. In a similar vein, Operation Warp Speed, initiated during the COVID-19 pandemic, successfully facilitated rapid vaccine development. While challenges abounded during the pandemic, the swift development of vaccines was a notable achievement.
With the looming crisis of Long COVID, there is a pressing need for similar leadership. Recommendations suggest that the current administration enhance its investment in innovative research aimed at discovering effective treatments. Yet, efforts by federal health agencies, particularly the NIH, have fallen short. Reports indicate that critical funding for research into Long COVID’s underlying mechanisms has waned, especially since 2025 when the Office for Long COVID Research and Practice was closed. Consequently, funding cuts were made under the misguided belief that this issue was no longer a concern.
Contrary to this perspective, the reality is stark. Long COVID is not just a lingering consequence; it continues to impose heavy economic burdens, costing the United States hundreds of billions annually in lost productivity and healthcare expenses. These costs are compounded by the premature termination of research programs that were on the brink of breakthroughs.
While some funding for Long COVID research has resumed, overall investment remains insufficient. The urgency for an aggressive, well-funded research campaign to address Long COVID cannot be overstated. Secretary Kennedy’s recent commitment to tackling chronic diseases is a commendable step, but the focus must shift toward the specific challenges posed by Long COVID.
The trajectory of AIDS offers a hopeful parallel: once viewed as an enigmatic and deadly disease, it has evolved into a condition that is now manageable with proper care. A similar future could be envisioned for Long COVID with the right investments in research and clinical trials, giving hope to millions suffering from its debilitating effects.
It is essential that federal health authorities step up to enable significant progress in the understanding and treatment of Long COVID. A concerted effort by HHS and industry is necessary to forge a path toward better outcomes for those affected, ultimately allowing millions to reclaim their lives from the grip of Long COVID.
"*" indicates required fields
